Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes

    ... Two demethylating agents, azacitidine and decitabine , are approved for treatment of MDS, though many patients do not ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Update on the pharmacotherapy for myelodysplastic syndromes

    ... lenalidomide , azacitidine and decitabine . AREAS COVERED: This review summarizes the major ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Molecular pathogenesis of myelodysplastic syndromes

    ... options for MDS, including lenalidomide , decitabine , and 5-azacytidine, are targeted to improve transfusion ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. How we treat higher-risk myelodysplastic syndromes

    ... the hypomethylating agents azacitidine and decitabine , which should be administered for a minimum of 6 cycles, and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Current therapy of myelodysplastic syndromes.

    ... therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last decade was a major ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Prognostic role of immunohistochemical analysis of 5mc in Myelodysplastic Syndromes.

    ... effectiveness; the drugs azacitidine and decitabine have been approved for the treatment of MDS. METHOD: We ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of myelodysplastic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Myelodysplastic syndromes: therapy and outlook

    ... such as lenalidomide , azacitidine , and decitabine are available for those who previously would have received ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Combination strategies in myelodysplastic syndromes.

    ... lenalidomide , azacitidine , and decitabine are the only three FDA-approved drugs for MDS. Traditional ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Hypomethylating agents for the treatment of myelodysplastic syndromes

    ... 5-azacytidine (azacitidine) and 5-deoxyazacytidine ( decitabine ). Clinical trials of hypomethylating agents in MDS still raise a ...

    Research Article last updated 07/20/2018 - 5:14pm.